Mislocalization of the exitatory amino-acid transporters (EAATs) in human astrocytoma and non-astrocytoma cancer cells: effect of the cell confluence

Journal of Biomedical Science

Marc Maresca¹  Soraya Graoudi¹  Amanda Azmi¹  Coralie Di Scala¹  Nadira Taïeb¹  Amal Benzaria¹  Karine Varini² 

[1] Aix-Marseille Université, Faculté des Sciences de St-Jérôme, 13397 Marseille Cedex 20, France;Interactions cellulaires neuroimmunes et pathologies du système nerveux central, CRN2M, CNRS UMR 6231, University of Aix-Marseille 2 and Aix-Marseille 3, Faculté de Médecine - Secteur Nord, Université de la Méditerranée, Marseille, France

关键词: STTG-1;    Mislocalization;    EAAT;    Glutamate;    GLT-1;    GLAST;    Cancer;    Astrocytoma;   

Others  :  825828
DOI  :  10.1186/1423-0127-19-10

 received in 2011-11-20, accepted in 2012-02-01,  发布年份 2012

【 摘 要 】

Background

Astrocytomas are cancers of the brain in which high levels of extracellular glutamate plays a critical role in tumor growth and resistance to conventional treatments. This is due for part to a decrease in the activity of the glutamate transporters, i.e. the Excitatory Amino Acid Transporters or EAATs, in relation to their nuclear mislocalization in astrocytoma cells. Although non-astrocytoma cancers express EAATs, the localization of EAATs and the handling of L-glutamate in that case have not been investigated.

Methods

We looked at the cellular localization and activity of EAATs in human astrocytoma and non-astrocytoma cancer cells by immunofluorescence, cell fractionation and L-glutamate transport studies.

Results

We demonstrated that the nuclear mislocalization of EAATs was not restricted to astrocytoma and happened in all sub-confluent non-astrocytoma cancer cells we tested. In addition, we found that cell-cell contact caused the relocalization of EAATs from the nuclei to the plasma membrane in all human cancer cells tested, except astrocytoma.

Conclusions

Taken together, our results demonstrated that the mislocalization of the EAATs and its associated altered handling of glutamate are not restricted to astrocytomas but were also found in human non-astrocytoma cancers. Importantly, we found that a cell contact-dependent signal caused the relocalization of EAATs at the plasma membrane at least in human non-astrocytoma cancer cells, resulting in the correction of the altered transport of glutamate in such cancer cells but not in astrocytoma.

【 授权许可】

   
2012 Varini et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
• [2]Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol 2005, 109:93-108.
• [3]Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
• [4]Noch E, Khalili K: Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther 2009, 8:1791-1797.
• [5]Roesler R, Brunetto AT, Abujamra AL, de Farias CB, Brunetto AL, Schwartsmann G: Current and emerging molecular targets in glioma. Expert Rev Anticancer Ther 2010, 10:1735-1751.
• [6]Sontheimer H: Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci 2003, 26:543-549.
• [7]Sontheimer H: A role for glutamate in growth and invasion of primary brain tumors. J Neurochem 2008, 105:287-295.
• [8]Amberger-Murphy V: Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 2009, 9:381-390.
• [9]Campos B, Herold-Mende CC: Insight into the complex regulation of CD133 in glioma. Int J Cancer 2010, 128:501-510.
• [10]Lino MM, Merlo A, Boulay JL: Notch signaling in glioblastoma: a developmental drug target? BMC Med 2010, 8:72. BioMed Central Full Text
• [11]Schiffer D, Annovazzi L, Caldera V, Mellai M: On the origin and growth of gliomas. Anticancer Res 2010, 30:1977-1998.
• [12]Wang DD, Bordey A: The astrocyte odyssey. Prog Neurobiol 2008, 86:342-367.
• [13]Ye ZC, Rothstein JD, Sontheimer H: Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 1999, 19:10767-10777.
• [14]Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H: Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007, 67:9463-9471.
• [15]Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H: Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 2005, 25:7101-7110.
• [16]Arcella A, Carpinelli G, Battaglia G, D'Onofrio M, Santoro F, Ngomba RT, Bruno V, Casolini P, Giangaspero F, Nicoletti F: Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol 2005, 7:236-245.
• [17]D'Onofrio M, Arcella A, Bruno V, Ngomba RT, Battaglia G, Lombari V, Ragona G, Calogero A, Nicoletti F: Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem 2003, 84:1288-1295.
• [18]Mordrelle A, Jullian E, Costa C, Cormet-Boyaka E, Benamouzig R, Tomé D, Huneau JF: EAAT1 is involved in transport of L-glutamate during differentiation of the Caco-2 cell line. Am J Physiol Gastrointest Liver Physiol 2000, 279:G366-373.
• [19]Sharma MK, Seidlitz EP, Singh G: Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun 2010, 391:91-95.
• [20]Post GR, Dawson G: Characterization of a cell line derived from a human oligodendroglioma. Mol Chem Neuropathol 1992, 16:303-317.
• [21]Razafimanjato H, Garmy N, Guo XJ, Varini K, Di Scala C, Di Pasquale E, Taïeb N, Maresca M: The food-associated fungal neurotoxin ochratoxin A inhibits the absorption of glutamate by astrocytes through a decrease in cell surface expression of the excitatory amino-acid transporters GLAST and GLT-1. Neurotoxicology 2010, 31:475-484.
• [22]Razafimanjato H, Benzaria A, Taïeb N, Guo XJ, Vidal N, Di Scala C, Varini K, Maresca M: The ribotoxin deoxynivalenol affects the viability and functions of glial cells. Glia 2011, 59:1672-1683.
• [23]Maresca M, Mahfoud R, Pfohl-Leszkowicz A, Fantini J: The mycotoxin ochratoxin A alters intestinal barrier and absorption functions but has no effect on chloride secretion. Toxicol Appl Pharmacol 2001, 176:54-63.
• [24]Luksch H, Uckermann O, Stepulak A, Hendruschk S, Marzahn J, Bastian S, Staufner C, Temme A, Ikonomidou C: Silencing of selected glutamate receptor subunits modulates cancer growth. Anticancer Res 2011, 31:3181-3192.
• [25]Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170:1445-1453.